# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Babe Didrikson Zaharias (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML038-SYN
- Date: 2026-04-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Vasquez-Thornbury, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Day 1 of cycle 2 of dostarlimab. **S**

## History of present illness

Ms. Didrikson Zaharias comes before her second dose of dostarlimab. The first dose three weeks ago caused no reaction. Within ten days the bleeding became occasional streaks, and for the last week there has been none; her stools are a normal shape and the urgency has eased. She has had no diarrhea, rash, cough, breathlessness, headache or thirst. She has taken ferrous sulfate every other morning for four weeks, with mild constipation that settled with more fruit, and she is less tired. She is practicing every day and played 18 holes twice last week. The germline panel was negative, and tumor sequencing found two changes in MSH2 in the tumor itself, which explains the mismatch repair deficiency. She asked what this means for her brothers and sisters. **S**

| Element | Detail |
|---|---|
| Treatment | Dostarlimab cycle 1 three weeks ago; cycle 2 today |
| Symptoms | No bleeding for a week; normal stools; less tired |
| Adverse events | None |
| Genetic results | Germline panel negative; two somatic MSH2 variants in the tumor |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; no fever; weight 63.2 kg |
| Gastrointestinal | Negative | No bleeding for a week; no diarrhea or abdominal pain; mild constipation from iron, settled |
| Integumentary | Negative | No rash or itching |
| Respiratory | Negative | No cough or breathlessness |
| Endocrine | Negative | No heat or cold intolerance, thirst or headache |
| Psychiatric | Negative | Hopeful; PHQ-9 4; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning **S**
- Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months) **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/68 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 63.2 kg; BMI 22.4 kg/m². All vital signs are synthetic.

Hemoglobin: 12.1 g/dL; MCV: 80 fL; White cell count: 6.2 10*3/uL; Platelets: 352 10*3/uL; Creatinine: 0.74 mg/dL; eGFR (CKD-EPI 2021): 104 mL/min/1.73 m²; Glucose: 92 mg/dL; ALT: 22 U/L; AST: 24 U/L; TSH: 2.2 mIU/L; Free T4: 1.2 ng/dL; CEA: 3.4 ng/mL (high); PHQ-9: 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 11 g/dL (low) at baseline, 12.1 g/dL at this visit **S**
- MCV: 77 fL (low) at baseline, 80 fL at this visit **S**
- White cell count: 6.8 10*3/uL at baseline, 6.2 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 352 10*3/uL at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.74 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 98 mL/min/1.73 m² at baseline, 104 mL/min/1.73 m² at this visit **S**
- Glucose: 88 mg/dL at baseline, 92 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 22 U/L at this visit **S**
- AST: 21 U/L at baseline, 24 U/L at this visit **S**
- CEA: 5.8 ng/mL (high) at baseline, 3.4 ng/mL (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 63.2 kg; blood pressure 110/68, pulse 70 |
| Skin | No rash |
| Neck | Thyroid not enlarged or tender |
| Abdomen | Soft, non-tender |
| Rectal | With her agreement and a chaperone: the mass is smaller and softer, with a flatter edge; no blood on the glove |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Low rectal adenocarcinoma, mismatch repair deficient, on dostarlimab** (C20). An early clinical response after one dose: the bleeding has stopped, the tumor is smaller to the finger, and CEA has fallen from 5.8 to 3.4 ng/mL. No immune-related adverse event; thyroid, liver and kidney tests normal. The germline panel found no pathogenic variant in MLH1, MSH2, MSH6, PMS2, EPCAM or the other colorectal cancer genes, and tumor sequencing found two somatic MSH2 variants, so this is a sporadic mismatch repair-deficient cancer rather than Lynch syndrome. Her first-degree relatives still have a raised risk because she had colorectal cancer young, and are advised to start colonoscopy at 40, or 10 years before her age at diagnosis if that is earlier, and repeat it every five years. Hepatitis B, hepatitis C and HIV tests were negative; hepatitis B surface antibody was negative, so vaccination is due. **S**
   - Dostarlimab cycle 2 today.
   - A letter for her to share with her brothers and sisters, if she chooses, explaining their screening.
   - Restaging MRI, sigmoidoscopy and examination after four doses.
2. **Iron deficiency anemia from rectal blood loss** (D50.0). Hemoglobin up from 11.1 to 12.1 g/dL and MCV from 77 to 80 fL four weeks after starting oral iron, with the bleeding stopped. **S**
   - Continue ferrous sulfate every other morning.
   - Ferritin at about three months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count | Before each dose of dostarlimab and at each visit; about four weeks after oral iron starts | Completed today | Four weeks after oral iron: hemoglobin 12.1 g/dL, MCV 80 fL, white cells 6.2, platelets 352 |
| Laboratory | Kidney and liver function and glucose | Before each dose of PD-1 blockade | Completed today | Creatinine 0.74 mg/dL, eGFR 104; ALT 22 U/L, AST 24 U/L; glucose 92 mg/dL |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | TSH 2.2 mIU/L, free T4 1.2 ng/dL |
| Laboratory | CEA | During treatment, as a marker of response | Completed today | 3.4 ng/mL, down from 5.8 |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Mass smaller and softer; no blood |
| Examination | Immune-related adverse event review (diarrhea, rash, cough, breathlessness, fatigue, endocrine symptoms) | Before each dose | Completed today | None |
| Laboratory | Germline multigene panel and tumor sequencing | Germline result before treatment decisions that depend on it; tumor sequencing when the germline panel is negative | Completed today | Germline negative; two somatic MSH2 variants in the tumor; KRAS, NRAS and BRAF wild type |
| Self-management | Screening advice for first-degree relatives | Once the genetic results are known | Completed today | Colonoscopy from 40, or 10 years before her age at diagnosis if earlier, every five years; letter given for her to share as she chooses |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Up to date | All negative; hepatitis B surface antibody negative, so vaccination is due |
| Laboratory | Ferritin after oral iron | About three months after starting | Due | Due at the restaging visit |
| Imaging | Restaging pelvic MRI and flexible sigmoidoscopy | About every three months during treatment | Due | Booked for the week before cycle 5 |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 4; item 9 scored 0 |
| Self-management | Physical activity and sport | Each visit | Completed today | Playing 18 holes and practicing daily |

## Goal progress

- Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment. Outcome by 2026-03-30: Colonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeks. **S**
- Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis. Outcome by 2026-04-27: Germline panel negative; two somatic MSH2 variants in the tumor explain the deficiency. **S**
- Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved. In progress; target 2026-10-05. **S**
- Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL. In progress; target 2026-10-05. **S**
- Back to tournament golf during treatment. In progress; target 2026-06-29. **S**
- TSH within the reference range on thyroid replacement. In progress; target 2026-08-10. **S**
- PHQ-9 below 10 throughout treatment. In progress; target 2026-10-05. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026), National Comprehensive Cancer Network
- Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022), New England Journal of Medicine
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024), American Society of Clinical Oncology
- Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017), U.S. Multi-Society Task Force on Colorectal Cancer
- CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026), Aether Forge

## Follow-up

- Cycles 3 and 4 as booked; restaging MRI and sigmoidoscopy in about eight weeks; primary care review at cycle 5. **S**
- Next scheduled visit 2026-06-29: restaging after four doses: pelvic MRI and endoscopy, immune-related hypothyroidism, and the decision to continue PD-1 blockade. **S**
